Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2020-08-25 Capital/Financing Update
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - PTX 5 pages 27.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Prescient Therapeutics Limited regarding a proposed issue of securities, specifically a placement of ordinary fully paid shares. It details the number of securities to be issued, the issue price, the proposed issue date, and compliance with ASX listing rules. There is no financial data, financial statements, or detailed financial analysis present. The document is a formal notification of a capital raising event rather than a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief notice or a report publication announcement, but a substantive announcement about a financing activity.
2020-08-25 English
Appendix 4E and 2020 Annual Report 54 pages 1.1MB
Annual Report Classification · 100% confidence The document contains detailed financial data for the year ended 30 June 2020, including revenues, losses, net assets, and dividends information. It includes a Chairman's letter, review of operations, directors' report, auditor's independence declaration, financial statements (profit or loss, financial position, changes in equity, cash flows), notes to the financial statements, directors' declaration, and an independent auditor's report. The document explicitly states it is the "Annual Report of Prescient Therapeutics Limited for the year ended 30 June 2020." The length is substantial (15,000 characters), and it contains comprehensive financial and operational information typical of an annual report. Therefore, this document is the full Annual Report (10-K equivalent). FY 2020
2020-08-24 English
Appendix 4G and Corporate Governance Statement 25 pages 447.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references the ASX Corporate Governance Council Principles and Recommendations. It includes a key to corporate governance disclosures and mentions compliance with Listing Rule 4.10.3, which requires a corporate governance statement to be included in the annual report or made available on the company's website. The document is a form used to verify that the company has met disclosure requirements related to corporate governance, but it is not the corporate governance statement itself nor a full annual report. It is a regulatory filing submitted alongside the annual report to the ASX to confirm governance disclosures. The document length is 15,000 characters, indicating it is substantive but it is not a financial report or management report. It is best classified as a Regulatory Filing (RNS) because it is a compliance document related to governance disclosures and not a full report or announcement of voting results, management changes, or other specific filings.
2020-08-24 English
Appendix 2A 15 pages 195.5KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes details about the entity, the securities to be quoted, and references to previous announcements such as Appendix 3B. This type of document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document is a formal regulatory filing notifying the exchange and market of a securities quotation application, which fits best under the category of Regulatory Filings (RNS).
2020-08-23 English
Completion of $6.5 million Share Purchase Plan 3 pages 135.6KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 21 August 2020 from Prescient Therapeutics regarding the completion of a $6.5 million Share Purchase Plan (SPP). It details the amount raised, the number of new shares to be issued, and the expected trading dates. The content focuses on financing activity, specifically the successful completion of a capital raising event through a share purchase plan. There are no financial statements, quarterly or annual results, or management discussion of financial performance. The document is not a report but an update on a financing event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (8712 characters) is sufficient to provide substantive information about the financing event, not merely a brief notice or report publication announcement.
2020-08-20 English
Successful SPP Closed Early 3 pages 134.0KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 18 August 2020 from Prescient Therapeutics regarding the early closure of a Share Purchase Plan (SPP) due to overwhelming support. It includes details about the SPP timetable, a statement from the Non-Executive Chairman, and a description of the company's business and therapies. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is focused on a capital raising activity (the SPP) and its closure, which is a financing update. It is not a full financial report, earnings release, or regulatory filing about financial results. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (9163 characters) supports that it is a substantive announcement rather than a brief notice or report publication announcement.
2020-08-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.